Kinoshita Manabu, McDannold Nathan, Jolesz Ferenc A, Hynynen Kullervo
Department of Radiology, Brigham and Womens Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Biochem Biophys Res Commun. 2006 Feb 24;340(4):1085-90. doi: 10.1016/j.bbrc.2005.12.112. Epub 2005 Dec 27.
The blood-brain barrier (BBB) is a persistent obstacle for the local delivery of macromolecular therapeutic agents to the central nervous system (CNS). Many drugs that show potential for treating CNS diseases cannot cross the BBB and there is a need for a non-invasive targeted drug delivery method that allows local therapy of the CNS using larger molecules. We developed a non-invasive technique that allows the image-guided delivery of antibody across the BBB into the murine CNS. Here, we demonstrate that subsequent to MRI-targeted focused ultrasound induced disruption of BBB, intravenously administered dopamine D(4) receptor-targeting antibody crossed the BBB and recognized its antigens. Using MRI, we were able to monitor the extent of BBB disruption. This novel technology should be useful in delivering macromolecular therapeutic or diagnostic agents to the CNS for the treatment of various CNS disorders.
血脑屏障(BBB)是将大分子治疗剂局部递送至中枢神经系统(CNS)的一个长期存在的障碍。许多显示出治疗中枢神经系统疾病潜力的药物无法穿过血脑屏障,因此需要一种非侵入性靶向药物递送方法,以便使用更大的分子对中枢神经系统进行局部治疗。我们开发了一种非侵入性技术,可实现抗体在图像引导下穿过血脑屏障进入小鼠中枢神经系统。在此,我们证明,在MRI靶向聚焦超声诱导血脑屏障破坏后,静脉注射的多巴胺D(4)受体靶向抗体穿过血脑屏障并识别其抗原。利用MRI,我们能够监测血脑屏障破坏的程度。这项新技术在将大分子治疗或诊断剂递送至中枢神经系统以治疗各种中枢神经系统疾病方面应该会很有用。